Health Informatics Systems for Information and Decisional Control in Cancer Patients' Medical Decision-Making

Health Informatics Systems (HIS) are technology-based solutions that enhance healthcare efficiency by collecting, managing, and analyzing health data, including electronic health records, clinical decision support systems, and telemedicine platforms. HISs utilize technology to manage healthcare data, improve patient care, and enhance decision-making. The aim is to develop and evaluate HIS that enhances information management and decisional control in cancer patients' medical decision-making, ensuring informed and patient-centered care. The research surveyed 412 individuals who had been diagnosed with cancer. To ensure a diverse patient population, participants were selected from multiple healthcare institutions. The analysis utilized the Control Preferences Scale (CPS) to assess patients' preferred level of involvement in medical decisions. Patients were grouped into four decision-making categories: self-reliant, guided decision-making, co-decision, and non-participatory. The data was analyzed using SPSS 26 software to guarantee methodological rigor and reliability. Descriptive statistics, logistic regression, and analysis of variance (ANOVA) compare means across multiple groups to determine whether significant differences exist in decision-making preferences among cancer types. Self-reliance and guided decision-making are prevalent in the early stages, while non-participatory decision-making increases in the advanced stages. Logistic regression shows significant associations between HIS usage and decision-making styles. ANOVA confirms statistical differences in decision-making approaches across different patient groups. The findings highlight the diverse decision-making preferences among cancer patients, emphasizing the need for tailored HIS that support informed, and patient-centered care. Enhancing real-time data access and predictive insights can empower patients and improve collaborative decision-making in oncology.